Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.53 |
| ▸ | HBB | P68871 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7879764 | 0.95 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1CYP3A4KDM4EMEN1 | |
| SCHEMBL2997554 | 0.93 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1CYP3A4KDM4EMEN1 | |
| SCHEMBL7569937 | 0.88 | MAOB (0.55) | SMN1; SMN2ALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL5316111 | 0.85 | MAPT (0.66) | SMN1; SMN2ALDH1A1CYP3A4KDM4EMEN1 | |
| SCHEMBL5549472 | 0.85 | ALDH1A1 (0.64) | SMN1; SMN2ALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL5549511 | 0.84 | TDP1 (0.54) | SMN1; SMN2ALDH1A1CYP3A4KDM4EMEN1 | |
| SCHEMBL29764012 | 0.84 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1CYP3A4KDM4EMEN1 | |
| SCHEMBL23850 | 0.84 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1CYP3A4KDM4EMEN1 | |
| SCHEMBL11855895 | 0.83 | ACHE (0.57) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2992849 | 0.82 | MAOA (0.52) | SMN1; SMN2ALDH1A1CYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147093-B1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | SMN1; SMN2 1462/4885ALDH1A1 393/4885CYP3A4 449/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | SMN1; SMN2 1462/4885ALDH1A1 393/4885CYP3A4 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.